Atrial Fibrillation Management 2011

The North American Thrombosis Forum’s Prevention Forum 2011:

Atrial Fibrillation Management in 2011: A New State-of-the-Art

Thursday, April 28th 2011

Joseph B. Martin Conference Hall in Harvard Medical School

Forum will be held in the Evening

---

Videos from the event

---

Program Overview

The Thrombosis Prevention Forum 2011 is a comprehensive multidisciplinary conference addressing major issues concerning arterial and venous thrombosis. This year’s Forum is entitled “Atrial Fibrillation Management in 2011: A New State-of-the-Art.” The Forum’s objective is to improve patient care through the advancement of thrombosis and cardiovascular education. State-ofthe- art presentations will incorporate perspectives from clinical research, prevention efforts, educational initiatives, and advocacy. More than 30% of the curriculum is devoted to discussion, questions, and answers. This is a unique educational experience, allowing patients and their families to interact with the healthcare professionals who carry out research, provide clinical care, and work on public policy or advocacy issues related to thrombosis and cardiovascular disease.

REGISTER NOW

Target Audience

This program is intended for patients, advocates, office-based physicians, hospitalists, nurse practitioners, nurses, pharmacists, physician assistants, hospital administrators, and policy makers.

Location

This program will be held at the Joseph B. Martin Conference Center at Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115.

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Utah School of Medicine and The North American Thrombosis Forum (NATF). The University of Utah School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit: The University of Utah School of Medicine designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: Application for nursing continuing education credit for the Thrombosis Prevention Forum 2011 has been submitted to the University of Utah College of Nursing for consideration. The University of Utah College of Nursing is an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Pharmacists: The Utah Pharmacists Association (UPhA) is accredited by the Accreditaton Council for Pharmacy Education as a provider of continuing pharmacy education. Application for 2.75 contact hours (.275 CEUs) of credit for pharmacists has been submitted to UPhA for approval. This program is designed for all pharmacists.

Nondiscrimination and Disability Accommodation Statement: The University of Utah does not exclude, deny benefits to, or otherwise discriminate against any person on the basis of race, color, national origin, sex, disability, age, veteran’s status, religion, gender identity/expression, genetic information, or sexual orientation in admission to or participation in its programs and activities. Reasonable accommodations will be provided to qualified individuals with disabilities upon request, with reasonable notice. Requests for accommodations or inquiries or complaints about University nondiscrimination and disability/access policies may be directed to the Director, OEO/AA Title IX/Section 504/ADA Coordinator, 201 S President’s Circle, RM 135, Salt Lake City, UT 84112, 801-581-8365 (Voice/TTY), 801-585-5746 (Fax).

Speaker Series: Important takeaway points for attendees registered for the Atrial Fibrillation Management Program and the DVT Prophylaxis Strategies Program.

Atrial Fibrillation Management
Thursday, April 28, 2011 – 4PM-9PM

“ The evaluation and main agent of atrial fibrillation is undergoing a dramatic “paradigm shift” at the time when the incidence and prevalence of this arrhythmia is peaking. Based on this trifecta of emerging therapies, including innovative technologies for AF ablation, novel antiarrhythmic medications and alternatives to vitamin K antagonists, it is evident that these novel approaches have considerable promise to fundamentally alter the clinical management of AF. However, for any of these therapies to be truly considered a “paradigm shift” in the management of AF, the gap between this promise and clinical practice will have to be bridged with sufficiently robust evidence to result in changes in AF management guidelines. This presentation will focus on the current and emerging roles of these therapies.” – N.A. Mark Estes III M.D.

N.A. Mark Estes, MD is a Professor in Tufts University School of Medicine, Director of Cardiac Arrhythmia Center, and Director of Cardiac Electrophysiology and Pacemaker Laboratory at Tufts Medical Center in Boston, MA.

DVT Prophylaxis Strategies
Friday, April 29, 2011 – 7:30AM – 1PM

“Cancer-associated thrombosis is a leading cause of death in cancer patients. One-fifth of all thrombotic events occur in patients with cancer and this represents a major public health burden. Venous thromboembolism (VTE) can, however, be prevented in specific high-risk settings. Cancer patients who are hospitalized and those who are recovering from surgery are at high risk for thromboembolism (for periods up to 4 weeks after surgery) and prophylaxis with low-molecular-weight heparins (LMWHs) is highly effective and safe. Providers and health systems must work together to ensure that appropriate patients receive thromboprophylaxis during this high-risk period, including during the transition to home. Ongoing studies are utilizing risk model and biomarkers to identify high-risk patients in the outpatient setting. “ – Alok A. Kohrana, M.D., FACP

Alok A. Khorana, MD, FACP is Vice-Chief of the Division of Hematology/Oncology and Associate Professor of Medicine and Oncology at the James P. Wilmot Cancer Center at the University of Rochester in New York.

“Our current U.S. healthcare model is simply not sustainable. High healthcare costs and a failure to systematically deliver basic quality interventions are, in part, catalysts to our changing healthcare system wherein there is increasing accountability driven by incentives, penalties, and greater transparency. Hospital based care is a prime target to systematically address this quality gap because hospital care accounts for over a third of all healthcare expenditures and hospitalized patients are vulnerable to transitions of care. Hospitalists, whose primary focus is the care of hospitalized patients, are a rapidly growing specialty that must help lead this charge. As an example, the prevention of venous thromboembolism (VTE) provides a critical, high yield, quality improvement opportunity for the Hospitalist, wherein evidence-based interventions can be systematically applied to improve prevention and associated patient outcomes. In this regard, hospitalists represent a key leverage point for administrators, other clinicians, and patient advocates to utilize in championing VTE best practices.” - Robert C. Pendleton, MD

Robert C. Pendleton is the Associate Professor of Medicine in University of Utah School of Medicine, Director of Thrombosis Service, Co-Director of the University of Utah Hospitalist Program and Division of General Internal Medicine University of Utah Health Center in Salt Lake City, UT.

---

This is an excellent course offered only every other year!

Attendees at the 2009 Cardiovascular Medicine: Update for the Practitioner Course gave it outstanding scores for content. The 2011 Course will be the best one yet, with many more breakout sessions and an outstanding panel of 54 speakers including:

• Peter Ganz, MD
• Eugene Braunwald, MD
• Peter Libby, MD
• Paul Ridker, MD
• Marc Pfeffer, MD
• Elliott Antman, MD

For more information and to register, CLICK HERE

Make a donation through PayPal, it's easy, safe and quick.

NATF • 368 Boylston Street • Brookline, MA 02445 • Phone: (617) 730-4120 • FAX: (617) 738-7652 • Contact Us • Terms of Use
© 2012 North American Thrombosis Forum, Inc.